[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625374":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":26,"locations":11,"responsibleParty":32,"collaborators":11,"id":36,"slug":11,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":11,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":11,"enrollmentInfo":44,"targetDuration":11,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":11,"overallStatus":53,"whyStopped":11,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":11},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face).","EXPERIMENTAL",null,[13],"Drug: topical dutasteride",{"label":15,"type":10,"description":11,"interventionNames":16},"Topical Dutasteride 0.05% gel versus topical triple fixed-dose combination",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","topical dutasteride","* Group I will be treated by topical Dutasteride 0.05% gel versus placebo (Petrolatum) (split face).\n* Group II will be treated by topical Dutasteride 0.05% gel versus topical triple fixed-dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% gel (split face).",[9,15],[24,25],"Dutasteride","Triple fixed combination",[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Ola A Elminshawy, M.Sc.","CONTACT","+201112693230","ola-elminshawy@aun.edu.eg",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ola Ahmed Elminshawy","Principal investigator","100625374",false,"NCT07421804","Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","Clinical and Microbiological Evaluation of Topical Dutasteride as a Potential New Therapy of Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","Inclusion Criteria:\n\n* Patients with facial acne vulgaris older than 18 years.\n\nExclusion Criteria:\n\n* · Unrealistic expectations.\n\n  * Unable to follow up.\n  * Severe and nodulocystic AV.\n  * Patients on topical treatment for AV (4 weeks before enrollment) and on systemic treatment for AV (3 months before enrollment).\n  * Patients on any systemic medication 3 months before enrollment.\n  * Suspicion of malignancy, including prostate cancer\n  * History of infertility or difficulty in fathering children.\n  * Pregnancy \\& lactation.\n  * Planning to become pregnant during study period or 6 months after ending treatment\n  * Patients with any concomitant dermatologic or systemic illness.","ALL","18 Years",{"count":45,"type":46},50,"ESTIMATED","INTERVENTIONAL",[49],"NA","Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience emotional distress, lower self-esteem and anxiety disorders .\n\nAcne Vulgaris is a chronic inflammatory skin condition affecting the pilosebaceous units that leads to the development of different skin lesions such as comedones, papules, pustules, nodules and cystic lesions .",[52],"Acne Vulgaris","NOT_YET_RECRUITING","2026-02-12",{"date":56,"type":57},"2026-02-19","ACTUAL",{"date":59,"type":46},"2026-04",{"date":61,"type":46},"2028-04",{"name":5,"class":6}]